Contents
Issue 138 • January 2024
In association with
In Depth
Pharma’s path to Net Zero: Targeting Scope 3 emissions
Profit vs inquiry: Clash of objectives in academic and commercial trials
CTO Europe 2023: A snapshot of challenges and opportunities in oncology
The future of cell and gene therapy manufacturing
VPAS is dead, long live VPAG
European Pharmaceutical legislation: hindrance or help?